
Hai V. Nguyen
Examiner (ID: 249)
| Most Active Art Unit | 2649 |
| Art Unit(s) | 2152, 2142, 2618, 2649, 2647 |
| Total Applications | 1496 |
| Issued Applications | 1169 |
| Pending Applications | 146 |
| Abandoned Applications | 211 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17706006
[patent_doc_number] => 20220206012
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS
[patent_app_type] => utility
[patent_app_number] => 17/393267
[patent_app_country] => US
[patent_app_date] => 2021-08-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14801
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17393267
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/393267 | METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS | Aug 2, 2021 | Pending |
Array
(
[id] => 20264153
[patent_doc_number] => 12435129
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-10-07
[patent_title] => Anti-Ab antibodies
[patent_app_type] => utility
[patent_app_number] => 17/383765
[patent_app_country] => US
[patent_app_date] => 2021-07-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 39
[patent_figures_cnt] => 49
[patent_no_of_words] => 19170
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 104
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17383765
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/383765 | Anti-Ab antibodies | Jul 22, 2021 | Issued |
Array
(
[id] => 18237686
[patent_doc_number] => 20230069996
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-09
[patent_title] => LIGAND-BINDING FUSION PROTEINS
[patent_app_type] => utility
[patent_app_number] => 17/793587
[patent_app_country] => US
[patent_app_date] => 2021-07-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56958
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 78
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793587
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/793587 | LIGAND-BINDING FUSION PROTEINS | Jul 19, 2021 | Pending |
Array
(
[id] => 17368368
[patent_doc_number] => 20220023420
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-27
[patent_title] => FUSION CONSTRUCTS AND METHODS OF USING THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/305577
[patent_app_country] => US
[patent_app_date] => 2021-07-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 84669
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17305577
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/305577 | Fusion constructs and methods of using thereof | Jul 8, 2021 | Issued |
Array
(
[id] => 18550783
[patent_doc_number] => 20230248783
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-10
[patent_title] => METHOD AND COMPOSITION FOR ENHANCING CANCER TREATMENT EFFICACY OF BACTERIA EXTRACELLULAR VESICLES
[patent_app_type] => utility
[patent_app_number] => 18/012498
[patent_app_country] => US
[patent_app_date] => 2021-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7650
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18012498
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/012498 | METHOD AND COMPOSITION FOR ENHANCING CANCER TREATMENT EFFICACY OF BACTERIA EXTRACELLULAR VESICLES | Jun 21, 2021 | Pending |
Array
(
[id] => 17399635
[patent_doc_number] => 20220041725
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-10
[patent_title] => Combination Therapy for the Treatment of Cancer
[patent_app_type] => utility
[patent_app_number] => 17/351724
[patent_app_country] => US
[patent_app_date] => 2021-06-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37380
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17351724
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/351724 | Combination Therapy for the Treatment of Cancer | Jun 17, 2021 | Abandoned |
Array
(
[id] => 20179509
[patent_doc_number] => 20250263467
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-08-21
[patent_title] => ANTIBODY THERAPIES FOR SARS-COV-2 INFECTION
[patent_app_type] => utility
[patent_app_number] => 18/001583
[patent_app_country] => US
[patent_app_date] => 2021-06-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 65682
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -88
[patent_words_short_claim] => 129
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18001583
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/001583 | ANTIBODY THERAPIES FOR SARS-COV-2 INFECTION | Jun 10, 2021 | Abandoned |
Array
(
[id] => 17297854
[patent_doc_number] => 20210393693
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use Thereof
[patent_app_type] => utility
[patent_app_number] => 17/342518
[patent_app_country] => US
[patent_app_date] => 2021-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 79137
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17342518
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/342518 | T-Cell Modulatory Multimeric Polypeptides with Conjugation Sites and Methods of Use Thereof | Jun 7, 2021 | Pending |
Array
(
[id] => 19667564
[patent_doc_number] => 12180292
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-12-31
[patent_title] => CD70 binding molecules and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 17/328118
[patent_app_country] => US
[patent_app_date] => 2021-05-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 45
[patent_figures_cnt] => 57
[patent_no_of_words] => 38265
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17328118
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/328118 | CD70 binding molecules and methods of use thereof | May 23, 2021 | Issued |
Array
(
[id] => 18707643
[patent_doc_number] => 20230330222
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-19
[patent_title] => SELECTIVE TARGETING OF THE TREML1/MD2 INTERACTION BY SMALL PEPTIDE OR PROTEIN AND ITS USE FOR VACCINE ADJUVANTS
[patent_app_type] => utility
[patent_app_number] => 17/998733
[patent_app_country] => US
[patent_app_date] => 2021-05-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4644
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998733
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/998733 | SELECTIVE TARGETING OF THE TREML1/MD2 INTERACTION BY SMALL PEPTIDE OR PROTEIN AND ITS USE FOR VACCINE ADJUVANTS | May 13, 2021 | Pending |
Array
(
[id] => 17067285
[patent_doc_number] => 20210269500
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-02
[patent_title] => CELL SURFACE COUPLING OF NANOPARTICLES
[patent_app_type] => utility
[patent_app_number] => 17/318590
[patent_app_country] => US
[patent_app_date] => 2021-05-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30684
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 78
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17318590
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/318590 | Cell surface coupling of nanoparticles | May 11, 2021 | Issued |
Array
(
[id] => 19840178
[patent_doc_number] => 12252547
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-03-18
[patent_title] => Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same
[patent_app_type] => utility
[patent_app_number] => 17/317824
[patent_app_country] => US
[patent_app_date] => 2021-05-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 108
[patent_figures_cnt] => 76
[patent_no_of_words] => 28186
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17317824
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/317824 | Affinity entities comprising a TCR-like antibody binding domain with high affinity and fine specificity and uses of same | May 10, 2021 | Issued |
Array
(
[id] => 17168805
[patent_doc_number] => 20210322475
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-21
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 17/307158
[patent_app_country] => US
[patent_app_date] => 2021-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12556
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -29
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17307158
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/307158 | COMPOSITIONS AND METHODS FOR TREATING CANCER | May 3, 2021 | Abandoned |
Array
(
[id] => 18434461
[patent_doc_number] => 20230181755
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY CONJUGATES, TRIFLURIDINE AND TIPIRACIL
[patent_app_type] => utility
[patent_app_number] => 17/916737
[patent_app_country] => US
[patent_app_date] => 2021-04-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10516
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17916737
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/916737 | ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY CONJUGATES, TRIFLURIDINE AND TIPIRACIL | Apr 21, 2021 | Pending |
Array
(
[id] => 18529970
[patent_doc_number] => 20230235037
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-27
[patent_title] => METHOD OF TREATMENT USING ANTI-CCL24 ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 17/996386
[patent_app_country] => US
[patent_app_date] => 2021-04-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26494
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17996386
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/996386 | METHOD OF TREATMENT USING ANTI-CCL24 ANTIBODY | Apr 19, 2021 | Pending |
Array
(
[id] => 17336099
[patent_doc_number] => 20220002430
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-06
[patent_title] => IMMUNOGLOBULIN VARIANTS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/235805
[patent_app_country] => US
[patent_app_date] => 2021-04-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 34363
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17235805
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/235805 | IMMUNOGLOBULIN VARIANTS AND USES THEREOF | Apr 19, 2021 | Abandoned |
Array
(
[id] => 18352583
[patent_doc_number] => 20230140694
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-04
[patent_title] => COMBINATION TREATMENT FOR CANCER INVOLVING ANTI-ICOS AND ANTI-PD1 ANTIBODIES, OPTIONALLY FURTHER INVOLVING ANTI-TIM3 ANTIBODIES
[patent_app_type] => utility
[patent_app_number] => 17/911937
[patent_app_country] => US
[patent_app_date] => 2021-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 87110
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17911937
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/911937 | COMBINATION TREATMENT FOR CANCER INVOLVING ANTI-ICOS AND ANTI-PD1 ANTIBODIES, OPTIONALLY FURTHER INVOLVING ANTI-TIM3 ANTIBODIES | Apr 11, 2021 | Abandoned |
Array
(
[id] => 17213174
[patent_doc_number] => 20210346510
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => Tetravalent Antibody-Drug Conjugates and Use Thereof
[patent_app_type] => utility
[patent_app_number] => 17/227536
[patent_app_country] => US
[patent_app_date] => 2021-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10146
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17227536
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/227536 | Tetravalent antibody-drug conjugates and use thereof | Apr 11, 2021 | Issued |
Array
(
[id] => 18420210
[patent_doc_number] => 20230174671
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 17/917726
[patent_app_country] => US
[patent_app_date] => 2021-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6930
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17917726
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/917726 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | Apr 8, 2021 | Pending |
Array
(
[id] => 18657752
[patent_doc_number] => 20230303706
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-28
[patent_title] => MONOCYTE
[patent_app_type] => utility
[patent_app_number] => 17/995815
[patent_app_country] => US
[patent_app_date] => 2021-04-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11672
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17995815
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/995815 | MONOCYTE | Apr 8, 2021 | Pending |